Robert Hoffman Buys Shares of FBLG $FBLG
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Robert Hoffman, insider at FibroBiologics, Inc. ($FBLG), bought 30,803 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
FibroBiologics, Inc. Stock Down 47.9%
Shares of FibroBiologics, Inc. ($FBLG) traded around $0.75 on Wednesday, down 47.9% for the day.
FibroBiologics, Inc. Earnings
Analysts Set New Price Targets
About FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Get FibroBiologics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $FBLG, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.